{"id":5137,"date":"2025-05-15T07:59:48","date_gmt":"2025-05-15T07:59:48","guid":{"rendered":"https:\/\/www.vampire-eu.com\/?page_id=5137"},"modified":"2026-01-20T15:52:48","modified_gmt":"2026-01-20T15:52:48","slug":"team","status":"publish","type":"page","link":"https:\/\/www.vampire-eu.com\/de\/team\/","title":{"rendered":"Team"},"content":{"rendered":"
\n

Meet the Team<\/h1><\/div><\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n

The Team<\/h2><\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Linkcare Health Services SL<\/a><\/span>

Robert Jenkins<\/h3><\/div><\/div>

Dr. Robert Jenkins holds a PhD in Molecular Neuroscience from the University of Cambridge and an MBA from IESE Business School. He has a solid track record in leading multidisciplinary teams, driving scientific innovation, and managing high-impact international projects. He is the current CEO of Linkcare Health Services, where he contributes his expertise in product development, technology transfer, and regulatory approval. Dr. Jenkins holds key positions at Ferrer InCode and Werfen, leading market access strategies, international agreements, and M&A processes in the in vitro diagnostics field. He also has extensive experience in global consulting and manages collaborative R&D projects involving clinical validation and market deployment across Europe, the United States, Latin America, and Asia.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Casa di Cura IGEA<\/a><\/span>

Elda Judica<\/h3><\/div><\/div>

Elda Judica, MD, is Neurologist, Neurophysiologist and Senior Researcher at Casa di Cura Igea, Milan. She is also Director of Igea Biobank, responsible of the Centers for Cognitive Disorders and Dementia and for the Rare Diseases. From 2018 she has been responsible for the clinical coordination of national and international European-funded projects such as Virtual Coaching activities for rehabilitation in elderly (vCare), pain in stroke (PainRelife), integrated care in Parkinson’s Disease (ProCare4Life), and more recently for the Horizon Europe project VaMPiRE on validation of biological biomarkers in Parkinson’s Disease. She is also actively involved in several clinical pharmacological trials as Sub investigator on Alzheimer\u2019s Disease and Principal Investigator on CIDP.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Asociaci\u00f3n Parkinson Madrid<\/a><\/span>

Mayca Mar\u00edn<\/h3><\/div><\/div>

Mayca Mar\u00edn is General Health Psychologist and Social Worker specialized in gerontology and innovation. She is the European and National Project Coordinator at APM, leading initiatives to improve life quality for people with Parkinson\u2019s disease. These include projects on health and social care, therapeutic support, volunteering, leisure, community engagement, and tech integration. She plays a key role in coordinating European projects promoting personalized, integrated care for older adults. Her expertise includes project management, cross-sector collaboration, and implementing innovative strategies. This is possible thanks to the work of APM\u2019s team of 60+ professionals and 100+ volunteers supporting over 1,800 people and families in Madrid.)<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Universitaetsmedizin Goettingen<\/a><\/span>

Tiago Outeiro<\/h3><\/div><\/div>

Tiago Outeiro graduated in Biochemistry at the University of Porto and did his PhD thesis at the Whitehead Institute for Biomedical research \u2013 MIT. Tiago was a Postdoctoral Research Fellow in the Department of Neurology of the Massachusetts General Hospital, Harvard Medical School, and is currently Full Professor and the Director of the Department of Experimental Neurodegeneration at the University Medical Center Goettingen, in Germany.
Tiago holds a joint Professor position at Newcastle University in the UK. Tiago has authored >360 research articles and participates in various international boards and in collaborative projects with the aim of identifying the molecular basis of neurodegenerative disorders such as Alzheimer\u2019s and Parkinson\u2019s disease.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Fondazione European Brain Research Institute Rita Levi<\/a><\/span>

Marco Feligioni<\/h3><\/div><\/div>

Marco Feligioni, Ph.D., ist Pharmakologe und leitet das Labor f\u00fcr posttranslationale Proteinmodifikationen und Neurotransmitter-Freisetzungsmechanismen am Europ\u00e4ischen Institut f\u00fcr Hirnforschung (EBRI) in Rom. Sein Forschungsschwerpunkt sind die molekularen Mechanismen neurodegenerativer Erkrankungen wie Alzheimer, Parkinson und ALS. Er untersucht den Einfluss posttranslationaler Modifikationen \u2013 insbesondere der SUMOylierung \u2013 auf neurodegenerationsbezogene Proteine, um deren sch\u00fctzende oder sch\u00e4dliche Rolle zu bestimmen. Dar\u00fcber hinaus erforscht er die SUMOylierung als peripheren Biomarker. Dr. Feligioni ist Autor zahlreicher Publikationen und Initiator und wissenschaftlicher Koordinator des VaMPiRE-Projekts sowie der Rolle des EBRI im Konsortium.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Almawave SPA<\/a><\/span>

Raniero Romagnoli<\/h3><\/div><\/div>

Raniero Romagnoli is the CTO at Almawave. Within Almawave Group he is also CEO at OBDA Systems. He is an expert in AI and NLP and he drives the company technology strategy while managing technical teams of R&D and Innovation and the product group. Raniero actively participates in various national and international initiatives in the field of AI, also in collaboration with market associations, research centers and academies, and is member of the quality assurance committee of different universities and member of a European language technology industry association. He is currently a contract professor at two universities and a business school, teaching AI and ML both to Executive and MBA students and to university students.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
SYNLAB Italia S.R.L.<\/a><\/span>

Mariarosaria Incoronato<\/h3><\/div><\/div>

Mariarosaria Incoronato, Ph.D., is a molecular biologist with over 20 years of experience in clinical research. She earned her Ph.D. in Genetics of Microorganisms from the University of Naples \u201cFederico II\u201d in 2004. From 2005 to 2022, she worked as a biologist and researcher at SDN\/IRCCS-SDN S.p.A., and also held teaching roles at the University of Naples \u201cFederico II\u201d. She has coordinated several research projects funded by the Italian Ministry of Health, focusing on biomarkers in oncology, fatty liver, and heart failure. She is the author of 46 international publications (h-index: 24). Since 2022, she has been Scientific Assistant at Synlab Italia, supporting scientific research and health innovation.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Universitat Aut\u00f2noma de Barcelona<\/a><\/span>

Salvador Ventura<\/h3><\/div><\/div>

Salvador Ventura is Professor of Biochemistry and Molecular Biology at UAB, ICREA Acad\u00e8mia researcher, and since 2024, Scientific Director of I3PT-CERCA. He earned his PhD in Biological Sciences in 1998 and trained at EMBL-Heidelberg, Harvard Medical School, and Karolinska Institutet. He leads the \u201cProtein Folding and Conformational Disorders\u201d group at IBB-UAB, which he directed from 2017 to 2020. His lab integrates computational and experimental approaches to develop therapies targeting protein aggregation. He has led 47 competitive projects, 11 industry collaborations, authored over 310 papers, supervised 20 PhD theses, co-invented 19 patent families, and co-founded Eureka NanoBioEngineering. He ranks among the top 2% most influential scientists globally and has received major national awards for his research excellence.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Aristotelio Panepistimio Thessalonikis<\/a><\/span>

Dimitrios Kazis<\/h3><\/div><\/div>

Dr. Dimitrios Kazis is an Associate Professor of Neurology at the School of Medicine, Aristotle University of Thessaloniki, and Head of the 3rd Department of Neurology at \u201cG. Papanikolaou\u201d Hospital. He earned his MD and PhD from Aristotle University and completed advanced training in Neurology, Psychiatry, and Clinical Neurophysiology in the UK, and the USA. His clinical and research focus includes Parkinson\u2019s disease, MS, and Alzheimer\u2019s disease. He has participated in numerous national and international studies and published 76 research articles indexed in PubMed. He is actively involved in several international boards and collaborative projects for Alzheimer\u2019s and Parkinson\u2019s disease.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Institut National De La Sant\u00e9 Et De La Recherche Medicale<\/a><\/span>

Chiara Guerrera<\/h3><\/div><\/div>

Chiara Guerrera, PhD, HDR<\/strong>
Director, Translational Proteomics Lab, INSERM, Paris. Expert in mass spectrometry-based proteomics for precision medicine. Leads platform development at Necker Hospital with over 100 collaborations. PhD (UCL), postdoc at WIBR. Technologies: DIA-MS, ion mobility, SILAC, ITRAQ. Co-organizer of national proteomics schools\/events, jury member for HCERES, PhD & HDR. 103 publications (H-index 26). Grants: Horizon EU, RHU, ANR, etc. Multilingual: IT, EN, FR, ES.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Instytut Psychiatrii I Neurologii<\/a><\/span>

Tomasz St\u0119pie\u0144<\/h3><\/div><\/div>

Tomasz St\u0119pie\u0144 is an Associate Professor of Medical Sciences at the Department of Neuropathology, Institute of Psychiatry and Neurology in Warsaw. He heads the Polish Brain Bank, one of the largest worldwide, and serves as Secretary of the Polish Association of Neuropathologists. He initiated the \u201cDigital Brain\u201d project and develops digital tools for neuropathology. He is the author and co-author of numerous publications in neuropathology, psychiatry, and neurology. His research focuses on neurodegenerative diseases and the interface between psychiatry and neurology. He holds a patent, teaches, promotes science, and coordinates the Polish part of the Horizon Europe project VaMPiRE.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
LEITAT<\/a><\/span>

Joan Marc Cabot<\/h3><\/div><\/div>

Dr. Joan Marc Cabot leitet die Gruppe f\u00fcr diagnostische Ger\u00e4te am LEITAT Technologiezentrum, wo er seit 2018 als Hauptforscher t\u00e4tig ist. Seine Forschungsschwerpunkte liegen auf patientennaher Diagnostik, Lateral-Flow-Tests und fortschrittlichen mikrofluidischen Plattformen zur schnellen Krankheitserkennung. Dr. Cabot erwarb seinen Bachelor- und Doktortitel in Analytischer Chemie an der Universit\u00e4t Barcelona und war als Forscher am ARC Centre of Excellence for Electromaterial Science (Australien) t\u00e4tig, unter anderem im Rahmen von Forschungsaufenthalten an der University of Washington (Australien) und der Dublin City University (Irland). Mit \u00fcber 15 Jahren Erfahrung hat er innovative Diagnosel\u00f6sungen entwickelt, die Biosensoren, Elektrofluidik und Organ-on-a-Chip-Systeme integrieren. <\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Universidad de Oviedo<\/a><\/span>

Maria Teresa Fern\u00e0ndez<\/h3><\/div><\/div>

M. Teresa Fern\u00e1ndez ist Ordentliche Professorin f\u00fcr Biochemie und Molekularbiologie an der Universit\u00e4t Oviedo und Direktorin des Instituts f\u00fcr Biotechnologie von Asturien (IUBA). Sie hat Chemie studiert und ein Aufbaustudium in Biochemie absolviert. Als Postdoktorandin arbeitete sie am National Cancer Institute (NIH, USA). Gemeinsam mit Dr. A. Novelli leitet sie seit 1990 eine Forschungsgruppe im Bereich der Neurowissenschaften an der Universit\u00e4t Oviedo. Ihre Forschung konzentriert sich auf die Mechanismen der Neurotoxizit\u00e4t und Neuroprotektion, wobei sie Prim\u00e4rkulturen von Neuronen und Gliazellen des zentralen Nervensystems verwendet, sowie auf die Untersuchung neuronaler elektrischer Aktivit\u00e4t mit der MEA-Technologie (Microelectrode Arrays) zur Analyse extrazellul\u00e4rer Signale, die von in vitro auf Mikroelektroden wachsenden neuronalen Netzwerken erzeugt werden.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Sapienza University of Rome<\/a><\/span>

Giovanni Fabbrini<\/h3><\/div><\/div>

Die Abteilung f\u00fcr Humanneurowissenschaften der Sapienza-Universit\u00e4t Rom vereint Grundlagenforschung und klinische Forschung in den Bereichen Neurologie, Psychiatrie, Neurochirurgie und Psychologie. Sie blickt auf eine Tradition zur\u00fcck, die bis ins Jahr 1883 reicht, und wird seit 2021 von Prof. Giovanni Fabbrini geleitet. Die Abteilung ist bekannt f\u00fcr bedeutende Beitr\u00e4ge wie die Elektrokrampftherapie. In den letzten Jahrzehnten hat sie sich durch nationale und internationale Kooperationen, hochrangige Publikationen und wissenschaftliche Veranstaltungen stetig weiterentwickelt und ihre starke Rolle in den Neurowissenschaften und der klinischen Versorgung beibehalten.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
University of Newcastle <\/a><\/span>

Murray Cairns<\/h3><\/div><\/div>

Professor Murray Cairns is head of the Centre for Complex Trait Genetics and Precision Medicine at the University of Newcastle, and the Chair of the Hunter Medical Research Institute Precision Medicine Research Program. Cairns has over 200 career publications, in journals such as Nature, Science, Cell, Nature Biotechnology, Nature Reviews Genetics, Nature Genetics, Nature Communications, Circulation.
Collectively, these have attracted more than 31,000 citations and highlight a significant international reputation in complex trait genetics and functional genomics. Cairns is an editorial board member of Epigenomics, American Journal of Medical Genetics, MicroRNA, Frontiers in Non-Coding RNA, Journal of RNA and Genomics, BioMedInformatics, International Journal of Molecular Science, Open Journal of Genomics.<\/em><\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n
\n
<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n

Dieses Projekt wurde im Rahmen des zweistufigen Programms HORIZON-HLTH-2024-DISEASE-03 der Europ\u00e4ischen Union gef\u00f6rdert. grant agreement No 101156370<\/a>.
Die ge\u00e4u\u00dferten Ansichten und Meinungen sind jedoch ausschlie\u00dflich die der Autorinnen und Autoren und spiegeln nicht notwendigerweise die der Europ\u00e4ischen Union oder von HORIZON-RIA wider. Weder die Europ\u00e4ische Union noch die F\u00f6rderbeh\u00f6rde k\u00f6nnen daf\u00fcr verantwortlich gemacht werden.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

The Team<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"enabled","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-5137","page","type-page","status-publish","hentry"],"yoast_head":"\nTeam - V\u03b1MPiRE<\/title>\n<meta name=\"description\" content=\"Parkinson's disease early detection\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vampire-eu.com\/de\/team\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Team - V\u03b1MPiRE\" \/>\n<meta name=\"twitter:description\" content=\"Parkinson's disease early detection\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/vampire-opengraph-1200x630-1.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"19\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.vampire-eu.com\/team\/\",\"url\":\"https:\/\/www.vampire-eu.com\/team\/\",\"name\":\"Team - V\u03b1MPiRE\",\"isPartOf\":{\"@id\":\"https:\/\/www.vampire-eu.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg\",\"datePublished\":\"2025-05-15T07:59:48+00:00\",\"dateModified\":\"2026-01-20T15:52:48+00:00\",\"description\":\"Parkinson's disease early detection\",\"breadcrumb\":{\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.vampire-eu.com\/team\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#primaryimage\",\"url\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg\",\"contentUrl\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.vampire-eu.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.vampire-eu.com\/#website\",\"url\":\"https:\/\/www.vampire-eu.com\/\",\"name\":\"V\u03b1MPiRE\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.vampire-eu.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.vampire-eu.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.vampire-eu.com\/#organization\",\"name\":\"V\u03b1MPiRE\",\"url\":\"https:\/\/www.vampire-eu.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png\",\"contentUrl\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png\",\"width\":512,\"height\":512,\"caption\":\"V\u03b1MPiRE\"},\"image\":{\"@id\":\"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/showcase\/biosomics\/about\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Team - V\u03b1MPiRE","description":"Parkinson's disease early detection","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vampire-eu.com\/de\/team\/","twitter_card":"summary_large_image","twitter_title":"Team - V\u03b1MPiRE","twitter_description":"Parkinson's disease early detection","twitter_image":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/vampire-opengraph-1200x630-1.jpg","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"19\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.vampire-eu.com\/team\/","url":"https:\/\/www.vampire-eu.com\/team\/","name":"Team - V\u03b1MPiRE","isPartOf":{"@id":"https:\/\/www.vampire-eu.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vampire-eu.com\/team\/#primaryimage"},"image":{"@id":"https:\/\/www.vampire-eu.com\/team\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg","datePublished":"2025-05-15T07:59:48+00:00","dateModified":"2026-01-20T15:52:48+00:00","description":"Parkinson's disease early detection","breadcrumb":{"@id":"https:\/\/www.vampire-eu.com\/team\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vampire-eu.com\/team\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.vampire-eu.com\/team\/#primaryimage","url":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg","contentUrl":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.vampire-eu.com\/team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vampire-eu.com\/"},{"@type":"ListItem","position":2,"name":"Team"}]},{"@type":"WebSite","@id":"https:\/\/www.vampire-eu.com\/#website","url":"https:\/\/www.vampire-eu.com\/","name":"V\u03b1MPiRE","description":"","publisher":{"@id":"https:\/\/www.vampire-eu.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vampire-eu.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.vampire-eu.com\/#organization","name":"V\u03b1MPiRE","url":"https:\/\/www.vampire-eu.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png","contentUrl":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png","width":512,"height":512,"caption":"V\u03b1MPiRE"},"image":{"@id":"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/showcase\/biosomics\/about"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"Pedro Sanchez","author_link":"https:\/\/www.vampire-eu.com\/de\/author\/slpedro\/"},"uagb_comment_info":0,"uagb_excerpt":"The Team","_links":{"self":[{"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/pages\/5137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/comments?post=5137"}],"version-history":[{"count":59,"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/pages\/5137\/revisions"}],"predecessor-version":[{"id":5583,"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/pages\/5137\/revisions\/5583"}],"wp:attachment":[{"href":"https:\/\/www.vampire-eu.com\/de\/wp-json\/wp\/v2\/media?parent=5137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}